OrthoPediatrics Corp. (Nasdaq: KIDS) announced its financial results for the third quarter ended September 30, 2026, reporting record revenue and updated guidance for the full year.
For the third quarter of 2026, the company generated total revenue of $72.7 million, a 19% increase compared to $61.2 million in the prior year period. This growth was driven by increases in both domestic and international markets, with U.S. revenue rising 19% to $57.9 million and international revenue increasing 18% to $14.8 million.
Revenue growth was primarily attributed to the company's Trauma & Deformity and OPSB product lines. Specifically, Trauma & Deformity revenue reached $52.6 million, up 19% year-over-year, while Scoliosis revenue increased 18% to $19.2 million.
On the profitability side, OrthoPediatrics reported a net loss of $5.9 million for the quarter, or $0.25 per share, a significant improvement from a net loss of $11.8 million, or $0.50 per share, in the same period last year. The company achieved a record adjusted EBITDA of $6.9 million and generated free cash flow of $1.6 million, a $5.0 million improvement compared to a $3.4 million cash outflow in the prior year.
OrthoPediatrics also announced an increase to its full year 2026 financial guidance. The company now expects revenue of $270.0 million to $273.0 million, representing 14% to 16% growth over 2025. Additionally, the company reiterated its expectation to achieve breakeven free cash flow in 2026.
